A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT04791319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Study identification
- NCT ID
- NCT04791319
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 199 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Bermekimab Drug
- Dupilumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2, 2021
- Primary completion
- Feb 1, 2022
- Completion
- Mar 30, 2022
- Last update posted
- Feb 28, 2023
2021 – 2022
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Allergy & Asthma Medical Group Inc. | Los Angeles | California | 90025 | — |
| Wolverine Clinical Trials | Santa Ana | California | 92705 | — |
| Park Avenue Dermatology | Orange Park | Florida | 32073 | — |
| Forcare Clinical Research, Inc. | Tampa | Florida | 33613 | — |
| Arlington Dermatology | Rolling Meadows | Illinois | 60008 | — |
| Dawes Fretzin Clinical Research Group | Indianapolis | Indiana | 46256 | — |
| Grekin Skin Institute | Warren | Michigan | 48088 | — |
| Psoriasis Treatment Center of Central New Jersey | East Windsor | New Jersey | 08520 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Ohio State University | Columbus | Ohio | 43215 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Clinical Partners | Johnston | Rhode Island | 02919 | — |
| Arlington Center for Dermatology | Arlington | Texas | 76011 | — |
| Austin Institute for Clinical Research | Pflugerville | Texas | 78660 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Center for Clinical Studies | Webster | Texas | 77598 | — |
| Virginia Clinical Research | Norfolk | Virginia | 23502 | — |
| Premier Clinical Research | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04791319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 28, 2023 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04791319 live on ClinicalTrials.gov.